Want to see HK:9955 full AI Analyst Report?
Top Page
ClouDr Group Limited
(9955)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.43
▼(-56.80% Downside)
Action:Reiterated
Date:10/13/26
The score is driven primarily by weak fundamentals—sharp revenue contraction and continued large net losses—despite improved gross margin and a move to positive operating cash flow. Technicals further weigh on the score as the stock trades below key moving averages with weak momentum. Valuation offers limited support because the negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
Improved Gross Margin
Gross margin rose to about 48% in 2025 from roughly 25% in 2023–2024, indicating materially better product economics. If retained, this improvement can provide more contribution per sale and create a stronger base for eventual operating leverage, even though profitability remains negative.
Negative Factors
Revenue Contraction
Revenue fell about 30% in 2025, following a more modest decline in 2024 and reversing strong growth in 2022–2023. Persistent contraction weakens scale, reduces the opportunity to spread fixed costs, and makes the improved gross margin harder to convert into sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Gross Margin
Gross margin rose to about 48% in 2025 from roughly 25% in 2023–2024, indicating materially better product economics. If retained, this improvement can provide more contribution per sale and create a stronger base for eventual operating leverage, even though profitability remains negative.
Read all positive factors
ClouDr Group Limited (9955) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$286.33M
Dividend YieldN/A
Average Volume (3M)114.53K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth-37.76%
EPS Growth60.28%
CountryHK
Employees776
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.65
Shares Outstanding645,718,800
10 Day Avg. Volume72,350
30 Day Avg. Volume114,534
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.00
Price to Sales (P/S)0.34
P/FCF Ratio-8.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)HK$7.73B
ClouDr Group Limited Business Overview & Revenue Model
Company Description
ClouDr Group Limited operates as an investment holding company, providing a diverse range of services within the healthcare sector. The firm supplies hospitals and pharmacies with crucial medical products, including devices like blood glucose mete...
How the Company Makes Money
ClouDr Group Limited primarily makes money by selling healthcare products to end customers through its retail channels. Its main revenue stream is retail sales generated in physical pharmacies and via online channels, with product categories gener...
ClouDr Group Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36B | 1.62B | 3.49B | 3.69B | 2.99B | 1.76B |
| Gross Profit | 737.81M | 775.08M | 861.67M | 909.38M | 792.10M | 570.02M |
| EBITDA | 24.16M | -508.87M | -372.34M | -208.37M | -1.58B | -4.06B |
| Net Income | -404.85M | -924.15M | -516.41M | -323.06M | -1.69B | -4.14B |
Balance Sheet | ||||||
| Total Assets | 1.47B | 1.68B | 2.84B | 2.95B | 2.83B | 2.51B |
| Cash, Cash Equivalents and Short-Term Investments | 442.74M | 449.77M | 532.16M | 595.10M | 723.17M | 1.12B |
| Total Debt | 210.16M | 288.75M | 581.24M | 267.05M | 228.67M | 9.03B |
| Total Liabilities | 1.03B | 1.20B | 1.41B | 1.18B | 953.05M | 9.66B |
| Stockholders Equity | 511.00M | 548.79M | 1.45B | 1.83B | 1.85B | -7.14B |
Cash Flow | ||||||
| Free Cash Flow | 13.49M | -65.22M | -225.19M | -263.46M | -809.87M | -755.02M |
| Operating Cash Flow | 48.28M | 82.38M | -148.39M | -140.43M | -642.63M | -666.33M |
| Investing Cash Flow | -98.93M | 9.33M | 66.87M | -38.34M | -744.94M | -155.50M |
| Financing Cash Flow | -59.78M | -32.72M | 147.99M | 171.81M | 503.55M | 1.02B |
ClouDr Group Limited Technical Analysis
Negative
1.00
Price Trends
0.49
Negative
0.54
Negative
0.67
Negative
Market Momentum
>-0.01
Negative
35.69
Neutral
28.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9955, the sentiment is Negative. The current price of 1 is above the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.49, and above the 200-day MA of 0.67, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 35.69 is Neutral, neither overbought nor oversold. The STOCH value of 28.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9955.
ClouDr Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.88B | 12.22 | 7.05% | 4.76% | 6.47% | 8.10% | |
65 Neutral | HK$46.19B | 5.61 | 8.33% | 5.34% | 2.78% | 7.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$593.46M | 10.89 | 7.70% | 6.25% | 14.25% | 0.83% | |
44 Neutral | HK$286.33M | -0.58 | -76.42% | ― | -37.76% | 60.28% | |
42 Neutral | HK$583.74M | -6.58 | -2.60% | 17.10% | -2.55% | -145.60% | |
41 Neutral | HK$381.46M | -5.60 | -273.18% | ― | 5.52% | 56.54% |
* Healthcare Sector Average
HK:9955
ClouDr Group Limited
0.45
-0.95
-68.21%
HK:0673
China Health Group
0.28
-0.18
-38.89%
HK:1099
Sinopharm Group Co
14.80
-2.77
-15.79%
HK:1931
IVD Medical Holding Limited
0.36
-8.52
-95.95%
HK:2192
Medlive Technology Co., Ltd.
6.60
-5.25
-44.34%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.50
<0.01
0.18%
ClouDr Group Limited Corporate Events
ClouDr Narrows Losses But Revenue Falls Nearly 30% in First-Half 2026
Aug 27, 2026
ClouDr Group Limited reported a sharp year-on-year revenue decline for the six months ended June 30, 2026, with total revenue falling 29.5% to RMB629.2 million as both in-hospital and out-of-hospital solutions contracted across subscription, value...
ClouDr Group Sets Board Meeting to Approve 2026 Interim Results
Aug 17, 2026
ClouDr Group Limited has scheduled a board meeting for August 27, 2026, to review and approve the interim financial results for the six months ended June 30, 2026. The meeting will also address the publication of these results and any other busine...
ClouDr Group Signals Sharp Narrowing of Interim Loss on AI-Driven Turnaround
Jul 24, 2026
ClouDr Group Limited reported that its consolidated net loss for the six months ended June 30, 2026 is expected to narrow sharply to between RMB60 million and RMB10 million, from RMB642.9 million a year earlier. The board attributed this improveme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.